Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Droxidopa
Drug ID BADD_D00732
Description Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease. Though L-DOPS has been used in Japan and Southeast Asia already for some time, it is also currently in clinical trials at the phase III point in the United States (U.S.), Canada, Australia, and throughout Europe. Provided L-DOPS successfully completes clinical trials, it could be approved for the treatment of neurogenic orthostatic hypotension (NOH) as early as 2011. Additionally, phase II clinical trials for intradialytic hypotension are also underway. Chelsea Therapeutics obtained orphan drug status (ODS) for L-DOPS in the U.S. for NOH, and that of which associated with Parkinson's disease , pure autonomic failure, and multiple system atrophy, and is the pharmaceutical company developing it in that country.
Indications and Usage Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Increased levels of norepinephrine in the central nervous system (CNS) may be beneficial to patients in a wide range of indications. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.
Marketing Status Prescription
ATC Code C01CA27
DrugBank ID DB06262
KEGG ID D01277
MeSH ID D015103
PubChem ID 92974
TTD Drug ID D0I3RO
NDC Product Code 67386-822; 70771-1611; 38217-0030; 31722-010; 68180-988; 27808-199; 69539-089; 70771-1610; 27241-200; 27241-201; 67877-704; 69539-146; 67386-820; 76278-1120; 69766-032; 59651-377; 69539-088; 67386-821; 69452-257; 31722-015; 53069-1060; 70436-140; 72205-073; 70710-1390; 58159-049; 68180-987; 0832-0720; 0832-0721; 70710-1391; 50228-429; 70710-1389; 63304-104; 70436-141; 70771-1609; 67877-705; 68180-989; 27808-201; 63304-086; 50228-431; 27808-200; 72205-072; 59651-376; 69452-256; 0054-0532; 0832-0722; 0054-0533; 59651-375; 63304-112; 72205-074; 50228-430; 27241-199; 67877-706; 42973-237; 0054-0534; 70436-142; 31722-014; 69452-258
Synonyms Droxidopa | threo-DOPS | threo DOPS | 3,4-threo-DOPS | 3,4 threo DOPS | DL-threo-3,4-Dihydroxyphenylserine | DL threo 3,4 Dihydroxyphenylserine | erythro-3,4-Dihydroxyphenylserine | erythro 3,4 Dihydroxyphenylserine | Droxidopa, (DL-Tyr)-Isomer | 3,4-Dihydroxyphenylserine | 3,4 Dihydroxyphenylserine
Chemical Information
Molecular Formula C9H11NO5
CAS Registry Number 23651-95-8
SMILES C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.007789%Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.0030.011498%
Abnormal dreams19.02.03.001; 17.15.02.0010.001113%Not Available
Acne23.02.01.001--Not Available
Acute respiratory failure22.02.06.001; 14.01.04.004--Not Available
Ageusia17.02.07.001; 07.14.03.003--Not Available
Aggression19.05.01.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.001--Not Available
Amnesia19.20.01.001; 17.03.02.0010.002967%
Amyloidosis10.02.05.0010.000339%Not Available
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Aneurysm24.02.01.0010.000242%Not Available
Anger19.04.02.001--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema10.01.05.009; 23.04.01.001--Not Available
Ankle fracture12.04.01.005; 15.08.03.0050.001484%
Anxiety19.06.02.002--
Aortic dissection24.02.03.0020.000371%Not Available
Aphasia19.21.01.001; 17.02.03.0010.001669%
Aphonia19.19.01.002; 17.02.08.009; 22.02.05.0240.000742%
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 17 Pages